

**LVTS - Laboratoire de recherche vasculaire  
translationnelle**  
Rapport Hcéres

► **To cite this version:**

Rapport d'évaluation d'une entité de recherche. LVTS - Laboratoire de recherche vasculaire translationnelle. 2018, Université Paris Diderot - Paris 7, Institut national de la santé et de la recherche médicale - INSERM, Université Paris 13. hceres-02031120

**HAL Id: hceres-02031120**

**<https://hal-hceres.archives-ouvertes.fr/hceres-02031120>**

Submitted on 20 Feb 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## REPORT ON THE RESEARCH UNIT:

Laboratory for Vascular Translational Science  
(LVTS)

## UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:

Institut national de la santé et de la recherche  
médicale - Inserm

Université Paris 13

Université Paris Diderot

**ÉVALUATION CAMPAIGN 2017-2018**  
GROUP D



In the name of Hcéres<sup>1</sup>:

Michel Cosnard, President

In the name of the expert committee<sup>2</sup>:

Yotis Senis, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

<sup>1</sup> The president of Hcéres "countersigns the evaluation reports set up by the expert committees and signed by their chairman." (Article 8, paragraph 5);

<sup>2</sup> The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

## UNIT PRESENTATION

<b>Unit name:</b>	Laboratory for Vascular Translational Science
<b>Unit acronym:</b>	LVTS
<b>Requested label:</b>	UMRS
<b>Application type:</b>	Renewal
<b>Current number:</b>	UMRS 1148
<b>Head of the unit (2017-2018):</b>	Mr Didier LETOURNEUR
<b>Project leader (2019-2023):</b>	Mr Didier LETOURNEUR and Mr Antonino NICOLETTI
<b>Number of teams:</b>	6

## COMMITTEE MEMBERS

<b>Chair:</b>	Mr Yotis SENIS, University of Birmingham, United Kingdom
<b>Experts:</b>	Ms Florence APPARAILLY, Université de Montpellier Mr Stéphane AVRIL, Université de Saint-Etienne Ms Reine BAREILLE, Inserm (supporting personnel) Mr Christophe BAUTERS, Université de Lille (representative of CNU) Ms Gisèle CLOFENT-SANCHEZ, Université de Bordeaux (representative of CoNRS) Mr Juergen SIEPMANN, Université de Lille (representative of Inserm CSS) Mr Fabrice SONCIN, Université de Lille

### HCERES scientific officer:

Ms Florence PINET

### Representatives of supervising institutions and bodies:

Mr Jean-Pierre ASTRUC, Université Paris 13

Ms Sylvie ROUSSET, Université Paris 7

Ms Sabrina SALNOUN, Inserm

## INTRODUCTION

### HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

Inserm unit 1148 (Inserm U 1148), also referred to as the Laboratory for Vascular Translational Science (LVTS), evolved from Inserm U698, created in partnership with Universities Paris 7 and Paris 13 in 2005. U 698 was originally comprised of three teams, led by Mr Jean-Baptiste Michel, who remains part of the unit (emeritus).

Inserm U 1148 is mainly located within a separate building on the site of Xavier Bichat Hospital, Paris, France. Technological platforms are partially offsite, at the Technological Institutes, University Paris 13.

### MANAGEMENT TEAM

As of 2012, Inserm U1148 was under the directorship of Mr Didier Letourneur. The head of the unit over the next five years (2019 - 2023) is Mr Didier Letourneur, and deputy head is Mr Antonino Nicoletti.

### HCERES NOMENCLATURE

SVE5\_2.

### SCIENTIFIC DOMAIN

The primary objectives of the unit are, understanding the molecular basis, diagnosis and treatment of cardiovascular disease. The unit takes a transdisciplinary and translational approach to achieving these objectives. In addition to basic science that underpins research into causes of cardiovascular disease and identification of biomarkers and drug targets, the unit coordinates large clinical trials; develops new diagnostic markers, imaging technologies / techniques and assays; and devises new therapeutic and biomaterial strategies. In addition, the unit has generated large clinical databases, human tissue and cell biobanks. This is a brief summary of research objectives of the 6 teams: team 1, Cardiovascular immunobiology; team 2, Vascular structural diseases; team 3, Cardiovascular bioengineering; team 4, Cardiovascular imaging; team 5, Atherothrombotic disease in the heart and brain; and team 6, which emerged from team 1, Hemostasis, thromboinflammation, neurovascular repair.

### UNIT WORKFORCE

Unit workforce	Number 30/06/2017	Number 01/01/2019
<b>Permanent staff</b>		
Full professors and similar positions	39	39
Assistant professors and similar positions	26	32
Full time research directors (Directeurs de recherche) and similar positions	7	7
Full time research associates (Chargés de recherche) and similar positions	6	6
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	0	0
High school teachers	0	0

Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	26	21
<b>TOTAL permanent staff</b>	<b>104</b>	<b>107</b>
<b>Non-permanent staff</b>		
Non-permanent professors and associate professors, including emeritus	2	
Non-permanent full time scientists, including emeritus, post-docs	37	
Non-permanent supporting personnel	13	
PhD Students	46	
<b>TOTAL non-permanent staff</b>	<b>98</b>	
<b>TOTAL unit</b>	<b>202</b>	

## GLOBAL ASSESSMENT OF THE UNIT

Many of the same key senior investigators have remained part of the unit throughout its existence, providing a solid foundation for the research currently taking place at the unit. This has also brought prestige and vision to the unit. The next five-year cycle will see key leaders within the unit retiring or nearing retirement, raising the need for successors to be identified and developed. There is a very strong next generation of scientists in place now in some of the teams.

The unit has been highly productive in terms of publications (>1400 including the top 1% of generalist journals) translational findings, patents (21) and two spinoff companies. The unit was very successful in obtaining grants such as 19 ANR, participation to 4 RHU and coordination of one RHU, 2 H2020 and one ERC. The unit is involved in training with 40 PhD theses defended and 48 ongoing PhD. Future directions and objectives of the unit are logical progressions of ongoing research within the unit that should yield further scientific, clinical and therapeutic breakthroughs.

The evaluation reports of Hceres  
are available online : [www.hceres.com](http://www.hceres.com)

**Evaluation of clusters of higher education and research institutions**  
**Evaluation of higher education and research institutions**  
**Evaluation of research**  
**Evaluation of doctoral schools**  
**Evaluation of programmes**  
**Evaluation abroad**



2 rue Albert Einstein  
75013 Paris, France  
T. 33 (0)1 55 55 60 10

[hceres.com](http://hceres.com)

[@Hceres\\_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)